Why Wharton’s Jelly MSC?
Wharton’s Jelly is a rich source of multi-potent stem cells.
Wharton’s Jelly Mesenchymal stem cells (MSCs) is increasingly becoming the preferential source of stem cells due to their relatively easier accessibility (large donor pool), non-invasive harvesting procedures with minimum risk and no discomfort to the donor. Not only it is high in vitro expandable rates and multipotent differential prospective, there are also no (ethical, race or religion) controversies surrounding the harvesting of Wharton’s Jelly.
The ability of such MSCs to differentiate into ectoderm/mesoderm/endoderm-derived cells implies that they contain promising latent regenerative characteristics medicine impending in several diseases. Current studies are steered towards taking full advantage of these distinctive properties for specific indications. The immunosuppressive ability of these cells provides potential lead in treating disorders such as graft-versus-host disease (GvHD), diabetes, Crohn’s disease, heart disease and solid tumor cancers.
For example, GvHD is a common complication succeeding a stem cell transplant from an unrelated donor. Due to MSCs distinctive immune properties, they showed a promising treatment possibility for steroid-refractory GvHD (when GvHD does not respond to steroids or is not resolved by steroids). Studies have also shown that MSCs verge to suppress autoimmune reactions and therefore, could potentially suppress the divergence between the graft and host immune systems.
- R, et al., Wharton’s Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes, June 2011,Volume 7, Issue 2, pp 342-363
- Corotchi, M.C, et al., Isolation method and xeno-free culture conditions influence multipotent differentiation capacity of human Wharton’s Jelly-derived mesenchymal stem cells, Stem Cell Research & Therapy 2013, 4:81
- R. Taghizadeh*, K.J. Cetrulo and C.L. Cetrulo, Wharton’s Jelly stem cells: Future clinical applications, 16 June 2011, doi:10.1016/ j.placenta.2011.06.010